New York, Jan 12, 2026, 3:33 PM EST — Regular session
- Shares of Synchrony dropped roughly 8% after renewed talk of a cap on card rates reignited concerns over regulatory pressures on lenders. (Reuters)
- Analysts noted that any rate cap would probably require congressional approval, but just the headline rattled sentiment around bank earnings this week. (Reuters)
- Separately, Synchrony revealed an expansion of CareCredit linked to Fiserv’s Clover platform. (PR Newswire)
Shares of Synchrony Financial dropped sharply on Monday, tumbling 8.2% to $79.76 in afternoon trading. The slide followed President Donald Trump’s push for a one-year cap on credit-card interest rates at 10%, a move investors warn could severely tighten card lending profits. (Reuters)
The proposal is significant since interest income drives card issuers’ profits, yet the cap is set well below prevailing rates. The Federal Reserve reported the average credit-card interest rate at 20.97% in November, highlighting just how steep a 10% limit would be. (Reuters)
Trump announced the cap would begin on Jan. 20 but didn’t explain how it would be enforced. On Truth Social, he said he was “calling for” the cap, yet offered no specifics on how companies would be forced to comply. (Reuters)
Wall Street analysts immediately highlighted legal and legislative hurdles. “It would take an Act of Congress for such rate caps to be in place,” UBS Global analysts noted, warning of probable legal battles if an executive order tried to enforce them. (Reuters)
The selloff took a toll on lenders connected to card balances. Bread Financial and Capital One dropped sharply, dragging down major banks with substantial card portfolios as well. (Barron’s)
Analysts flagged a risk that lenders might tighten credit, particularly targeting borrowers with weaker scores, instead of offering loans at unprofitable rates. J.P. Morgan’s Vivek Juneja cautioned this shift “could push more borrowing away from banks” and into alternative unsecured lending channels. (Reuters)
Barclays shares slipped in London as investors mulled potential fallout for companies tied to the U.S. card market. According to Hargreaves Lansdown senior equity analyst Matt Britzman, Barclays’ U.S. card business makes up about 11% of the group’s profits. (Reuters)
On Monday, Synchrony revealed it’s deepening the integration of its CareCredit offering with Clover, Fiserv’s POS system. The partnership now covers over 40,000 health and wellness providers using Clover devices. These providers can accept CareCredit payments and process applications right at the point of sale. (PR Newswire)
“Fully integrating CareCredit into Clover devices offers a significant operational edge,” said Beto Casellas, executive vice president and CEO of Health & Wellness at Synchrony. Katie Whalen from Fiserv added that the move is designed to help practices “operate more efficiently” and simplify payments. (PR Newswire)
The rate-cap idea remains just a concept for now, and investors might pull back if Washington doesn’t lay out a clear plan. A Jefferies analyst called it “highly unlikely” the proposal will pass, as markets weigh political noise against legal realities. (MarketWatch)
Upcoming on the calendar are key earnings reports. JPMorgan will release its numbers Tuesday, followed by Bank of America, Citigroup, and Wells Fargo later in the week. Investors will be watching closely for updates on consumer credit and how management addresses the risks tied to rate caps. (JPMorgan Chase)
Synchrony is set to release its fourth-quarter results on Jan. 27. (Synchrony)
